Neurogene NGNE
NASDAQ NGNE
$24.77 -0.33 (-1.31%)
As of: Nov 12, 2026 · 9:30 AM EST

Neurogene (NGNE) Gains (Losses) on Sale of Assets & Investments (2013 - 2023)

Updated

Neurogene (NGNE) reported Non Operating Investment Income of $7.83 million for FY2020.

Analysis

Neurogene (NGNE) Gains (Losses) on Sale of Assets & Investments (2013 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Neurogene 700.15 Mn -397.16 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 13,000.00
Jun 30, 2023 -31,000.00
Mar 31, 2023 39,000.00
Dec 31, 2022 71,000.00
Sep 30, 2022 -20,000.00
Jun 30, 2022 -72,000.00
Sep 30, 2020 7.83 Mn
Mar 31, 2014 134,553.00
Mar 31, 2013 29,396.00
API Access

Neurogene Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=NGNE&period=max&api_key=YOUR_API_KEY